Key result
Single-agent anti-angiogenic inhibitors show modest efficacy in angiosarcoma with median progression-free survival of ~4 months.
Why the study?
Angiosarcoma is a rare, aggressive endothelial malignancy that remains critically understudied with poor survival, leaving a gap in understanding molecular mechanisms and therapeutic strategies.
Answers are grounded in this paper and cite their sources.
This review highlights the complex mutational landscape of angiosarcoma and advocates for precision-medicine approaches and biomarker-guided combination therapies to improve outcomes in this aggressive malignancy.
Angiosarcoma is a rare, highly aggressive endothelial malignancy comprising less than 1% of soft tissue sarcomas, with a 5-year overall survival of only 41–43%. Despite advances in cancer therapeutics, angiosarcoma remains critically understudied due to limited case prevalence, perpetuating a knowledge gap in molecular mechanisms and therapeutic strategies. Recent clinical trials (Axi-STS, TAPPAS) demonstrated that single-agent anti-angiogenic inhibitors (axitinib, pazopanib) achieve modest efficacy (median progression-free survival (PFS) 3.0–4.3 months, response rates 5–13%), underscoring angiosarcoma’s complex, multipathway-driven pathogenesis. This review synthesizes the mutational landscape and molecular crosstalk of angiosarcoma, emphasizing four key mechanisms – (1) genepathway interactions—MYC amplification (>95% in radiation-associated angiosarcoma (RAAS)), TP53 mutations, and PIK3CA alterations converging to drive aggressive angiogenesis; (2) endothelial-specific dysregulation—TP53-driven disruption of VEcadherin junctions, VEGF-induced vascular permeability, and endothelial-tomesenchymal transition; (3) microenvironmental contributions— Transforming Growth Factor-Beta (TGF-β), IL-10, and VEGF-mediated immunosuppression and tumor progression; and (4) emerging biomarker-driven combinations—dual Vascular Endothelial Growth Factor (VEGF) + endoglin inhibition, chemotherapy + anti-PD-L1 immunotherapy, and multi-targeted TKI + Immune Checkpoint Inhibitors (ICI) strategies showing improved outcomes. Environmental exposures (vinyl chloride, thorotrast, radiation) drive distinct angiosarcoma subtypes with subtype-specific mutational profiles. We propose that precision-medicine approaches integrating molecular stratification, pathway crosstalk analysis, and biomarker-guided combination therapies represent the rational next steps to overcome therapeutic resistance and improve clinical outcomes in this lethal malignancy.
No takes yet. Share an insight, caveat, or question.
Pandey et al. (2026) conducted a review in Angiosarcoma. Single-agent anti-angiogenic inhibitors achieve modest efficacy in angiosarcoma, with median progression-free survival of 3.0–4.3 months and response rates of 5–13%.
Synapse has enriched 10 related papers. Consider them for comparative context: